Tariffs on Generic Drugs Could Lead to Shortages, Warns Former FDA Commissioner

Pharmaceutical Supply Chain Concerns

• 🇨🇳 China supplies approximately 70% of the key chemical substances used in drug manufacturing.
• 🇺🇸 About 50% of drugs consumed in the US are manufactured domestically, with 10% coming from Puerto Rico.
• 🇪🇺 The majority of the remaining 50% of drug value is imported from Europe, particularly Ireland, due to tax advantages for branded drugs.

Impact of Tariffs on Generic Drugs

• ⚠️ Tariffs on generic drugs, such as antibiotics, heparin, and amoxicillin, could lead to increased prices and companies ceasing production due to slim profit margins.
• 📉 Unlike branded drug companies, generic manufacturers have little cushion and may exit the market, potentially causing drug shortages.
• 🚫 The national security concerns cited for tariffs are unlikely to be resolved by this tool, as it may exacerbate the problem.

Strategies for Reshoring Pharmaceutical Manufacturing

• 🤝 A potential solution involves a grand bargain with the branded drug industry to incentivize bringing European-based manufacturing back to the US.
• 🚀 Branded companies like Eli Lilly and Novartis are already moving manufacturing back to the US, attracted by lower labor and energy costs.
• ⚙️ Expedited approvals from the FDA and environmental agencies, along with targeted subsidies, are needed to facilitate the move of China-based and India-based manufacturing back to the US.
• 📉 Moving the supply chain for low-margin generic products, often produced at a loss, back to the US will be challenging without significant administration support.

Bifurcating Solutions for Different Supply Chains

• 🇪🇺 The European drug manufacturing issue is primarily a trade deficit concern.
• 🇨🇳 The China-based supply chain issue is a national security concern, but requires different remedies than those applied to European imports.
• 🎯 The administration needs to treat these issues separately with tailored solutions.